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Abstract
Purpose In amyotrophic lateral sclerosis, functional alter-
ations within the brain have been intensively assessed, while
progression of lower motor neuron damage has scarcely been
defined. The aim of the present study was to develop a com-
putational method to systematically evaluate spinal cord me-
tabolism as a tool to monitor disease mechanisms.
Methods A new computational three-dimensional method to
extract the spinal cord from 18F-FDG PET/CT images was
evaluated in 30 patients with spinal onset amyotrophic lateral
sclerosis and 30 controls. The algorithm identified the skeleton
on the CT images by using an extension of the Hough trans-
form and then extracted the spinal canal and the spinal cord. In
these regions, 18F-FDG standardized uptake values were mea-
sured to estimate the metabolic activity of the spinal canal and
cord. Measurements were performed in the cervical and dorsal
spine and normalized to the corresponding value in the liver.
Results Uptake of 18F-FDG in the spinal cord was significantly
higher in patients than in controls (p < 0.05). By contrast, no
significant differences were observed in spinal cord and spinal
canal volumes between the two groups. 18F-FDG uptake was
completely independent of age, gender, degree of functional im-
pairment, disease duration and riluzole treatment. Kaplan-Meier
analysis showed a higher mortality rate in patients with standard-
ized uptake values above the fifth decile at the 3-year follow-up
evaluation (log-rank test, p < 0.01). The independence of this
value was confirmed by multivariate Cox analysis.
Conclusion Our computational three-dimensional method en-
abled the evaluation of spinal cord metabolism and volume
and might represent a potential new window onto the patho-
physiology of amyotrophic lateral sclerosis.
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Introduction
Neuroimaging with radionuclide methods allows the evalua-
tion of many features of the central nervous system.
However, while there is a large literature on the feasibility of
nuclear medicine in the study of the brain, its use in the evalu-
ation of the spinal cord (SC) has scarcely been investigated.
This can at least partially be explained by the morphology of
this nervous structure whose limited extension has prevented
the development of standardized methods to systematically an-
alyse its radioactivity uptake. To overcome this limitation – and
to expand functional evaluation to the SC – we have recently
developed a computational algorithm able to automatically rec-
ognize the spinal canal and SC in coregistered PET/CT images.
In the present study, we tested the accuracy and feasibility
of this approach. As a first validation step, the method was
applied to a series of patients with amyotrophic lateral sclero-
sis (ALS). Although this severe neurodegenerative disease
actually causes progressive damage to the upper and lower
motor neurons [1, 2], its evaluation by PET/CT imaging has
been limited to the motor cortex. Several studies have shown
the relevance of inflammatory signals in the motor cortex
related to microglial activation or lymphocyte/macrophage
infiltration [3–9] as possible correlates of disease phenotype
[10]. However, virtually none of these studies systematically
evaluated SC damage.
Extending the analysis to the lower motor neurons might
thus be a new approach to improving our understanding of the
heterogeneous nature of ALS. The clinical course of this se-
vere disease is variable with survival usually averaging
3 – 4 years from symptom onset [11] or more than 10 years
in a small number of patients [12]. As a consequence, our
computational algorithm and its potential to objectively define
the severity of SC involvement might complement the clinical
evaluation in defining disease aggressiveness.
Materials and methods
The study included 30 patients (20 men, mean age 66 ±
10 years, median 69 years, range 34 – 82 years) with definite,
probable or probable laboratory-supported spinal onset ALS
according to the revised El Escorial criteria [13]. All subjects
provided signed informed consent to be entered into the study
that was approved by the Ethics Committees of IRCCS AOU
San Martino-IST in Genova and of AUO Città della Salute e
della Scienza in Torino, Italy. The revised ALS functional
rating scale (ALSFRS-R, maximum score 48) [14] was used
to evaluate overall patient functional status at the time of the
study.
Data obtained in the patients were comparedwith data from
30 control subjects without any history of neurodegenerative
disease, randomly selected from a previously published
normalcy database [15] according to a case-control criterion
considering, age, sex and scanner used. This registry includes
patients who had a negative PET/CTscan 2 years after surgery
for a nonulcerated lesion, with a Breslow thickness less than
1 mm and negative sentinel node biopsy. Overall 10-year sur-
vival approaches 100 % in this population [16]. However, to
minimize the possible inclusion of cancer patients, enrolment
was delayed by 2 years after scanning so as to include only
those subjects who did not have any evidence of relapse or any
clinical event during this follow-up period.
PET/CT imaging
All subjects were studied in the early morning after fasting for
12 h. Serum glucose was assessed to ensure a glucose level
≤2 g/l. A bolus injection of FDG was administered
(4.8 – 5.2 MBq/kg body weight) with the patient lying in the
supine position in a quiet room and instructed not to move or
talk. A three-dimensional (3D) whole-body scan (arms down
position) was started 60 – 75 min after tracer administration
using an integrated PET/CT scanner (Hirez, Siemens Medical
Solutions; or Discovery, GE Healthcare).
Raw PET data were reconstructed into a 128 × 128 matrix
using a 3D iterative reconstruction algorithm (ordered-subsets
expectation maximization, three iterative steps, eight subsets).
Postfiltering with a 3D gaussian filter and scatter correction
were applied, and attenuation correction was performed using
the CT data. The resulting resolution was 4.0 mm full-width at
half-maximum for both scanners. The two imaging systems
were cross-calibrated according to the standard procedures for
quality control. In both centres, the PET scanners were peri-
odically calibrated with the same phantom, i.e. a cylinder of
20 cm outer diameter and 20 cm length filled with a solution
containing 100 MBq of 18F-FDG that was counted for 1 h to
minimize the statistical noise, while images were reconstruct-
ed with the same algorithm used for the clinical protocol.
The entire CT dataset was coregistered with the 3D PET
images using commercially available software interfaces. For
each patient, ideal body weight was calculated according to
the conventional formula of Robinson et al. [17]. The spinal
canal and SC were segmented from the low-dose CT data
acquired during the PET/CT scan to confirm the performance
of the analysis in a broad clinical setting.
Image analysis
The different spinal canal and SC districts were defined ana-
tomically considering the cervical segment as the region be-
tween the skull base and the plane adjacent to the caudal face
of the C7 vertebral body. The dorsal segment was defined as
the district between this plane and the one adjacent to the
caudal face of D12. The sacral and lumbar canal districts were
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a priori considered free from SC and were thus excluded from
the analysis.
Images were analysed according to a previously validated
method [18, 19] based on generalization of the Hough trans-
form technique for pattern recognition [20]. According to the
original definition [21], given a point P ¼ xP; yPð Þ in the im-
age plane satisfying the equation of a straight line
y ¼ axþ b ð1Þ
the Hough transform of P, with respect to the class of straight
lines, is the straight line of equation
yP ¼ axP þ b ð2Þ
into the parameter space where the two independent real pa-
rameters a, b vary [21]. This definition implies that all points
on the line (1) in the image space correspond to lines in the
parameter space that all intersect at the point (a, b) uniquely
identifying the original line. This correspondence between the
image and the parameter spaces holds not only for lines, but
also for several classes of algebraic curves. This simple fact
inspired the following pattern recognition algorithm for the
identification of curves in a digital image:
1. Apply the traditional Canny edge detection algorithm [22]
to extract discontinuities.
2. Compute the Hough transforms with respect to the select-
ed family of curves of all points in the image plane
highlighted by the edge detection process.
3. Discretize the parameter space into cells whose size is
optimized for the specific recognition problem (for the
recognition of SC the four-dimensional parameter space
is discretized with hypercubes with side equal to 0.02,
while for the recognition of the spinal canal the two-
dimensional parameter space is discretized with squares
with side again 0.02).
4. Construct an accumulator function defined on the
discretized parameter space such that for each cell the
value of the accumulator function is equal to the number
of Hough transforms passing through that cell.
5. Search for the parameter values identifying the cell where
the accumulator function reaches its maximum.
We applied this scheme to the recognition of both the
spinal canal and the SC districts in whole-body CT images
of control subjects and ALS patients. Specifically, the fam-
ily of curves with three convexities, represented by the
equation
Ca;b : x
2 þ y2 3 ¼ a x2 þ y2 −b x3−3xy2  2; ð3Þ
was particularly appropriate for the optimal detection of
the spinal canal (Fig. 1).
By contrast, the four-parameter family of ellipses expressed
in the form
Ea;b;c;d : b
2 x−cð Þ2 þ a2 y−dð Þ2−a2b2 ¼ 0 ð4Þ
was the best candidate for identifying the SC district. In
agreement with our previous experience [18, 19], visual
inspection by an experienced nuclear medicine physician
always confirmed the reliability of the segmentation
algorithm.
For each CT slice, the two curves identifying the spinal
canal and SC were used to create two sets of binary masks
with one zero outside and one inside each curve, respectively.
These masks were multiplied against the coregistered PET
slice in order to digitally extract the metabolic information
represented as standardized uptake value (SUV) of local
FDG radioactivity [23]. Finally, the average SUVs of both
spinal canal and SC were divided by the corresponding aver-
age SUV in the liver in order to account for possible differ-
ences in scanner sensitivity to obtain the normalized SUVs
(NSUVs). NSUVs of the whole SC were computed according
to the formula:
SC NSUV
¼ C NSUV  cervical SC volumeð Þ þ D NSUV  dorsal SC volumeð Þ
cervical SC volumeþ dorsal SC volume ;
ð5Þ
where C_NSUVand D_NSUV indicate the average NSUVof
the cervical and dorsal SC segments, respectively.
Statistical analysis
All data are reported as means ± SD. Unpaired or paired t tests
were used, as appropriate. Linear regression analysis was per-
formed using the least squares method. A p value <0.05 was
considered significant.
The 30 ALS patients were divided into two groups using
the fifth decile NSUV (0.67). Survival of these two groups
was analysed using the Kaplan-Meier method and compared
using the log-rank test. To assess the prognostic relevance of
the NSUV of the SC (SC_NSUV), a set of univariate and
multivariate Cox proportional hazard models were fitted to
the data. In the univariate analysis, the incidence of death
was modelled as a function of each of the following variables:
age, sex, time from ALS diagnosis to PET/CT scan, riluzole
therapy, ALS functional score and average SC_NSUV (below
and above the fifth decile). Then all six variables were tenta-
tively included in a multivariate Cox model by means of a
step-down (backward) procedure, based on the likelihood ra-
tio test: variables with a p value >0.1 were removed from the
model. Proportionality assumptions were assessed as previ-
ously described [24].
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Results
Clinical characteristics of the patients and controls
The main clinical findings in the ALS patients and control
subjects are shown in Table 1. According to the case-control
selection criterion, age, sex, and ideal body weight were sim-
ilar in the two groups. Similarly, serum glucose levels were
comparably low in the two groups (Table 1). The ALSFRS-R
score, updated for each patient on the day of imaging, ranged
from 20 to 46/48.
The time from ALS onset to PET/CT imaging was 18 ±
15 months (range 2 – 69 months, median 16 months). The
patients were followed up for 1 – 36 months after imaging
(median 14 months). During this period, 13 patients died from
respiratory complications (Table 1).
Shape and volume of spinal canal and spinal cord
The spinal canal profile significantly changed across the
whole stack of CT images. However, the Hough transform
method allowed the parameters of the curve with three con-
vexities to automatically change allowing the curve to opti-
mally adapt itself to the profile. The profile of the SC could be
recognized by the Hough transform of an ellipse for all spinal
districts. Further, the parameters of such an ellipse changed
less than 10 % in the cervical district and less than 12 % in the
dorsal district. This formulation did not change throughout the
Fig. 1 aDetection of spinal canal
and spinal cord at different
heights of the vertebral column.
The Hough transform-based pro-
cedure with respect to the curve
with three convexities allows
identification of the spinal canal
(blue line), while the spinal cord
is detected by the Hough
transform-based procedure with
respect to the ellipse (green line).
b Left to right: edge detection of a
CT slice in the vertebral region;
edge points inside the region
bounded by the curve with three
convexities; and the curve with
three convexities (blue line) and
the ellipse (green line) detected by
applying the Hough transform-
based procedure. c Left to right:
fusion of CTand PET data for the
slice considered in b zoomed on
the spinal region, and histograms
of the behaviour of the normal-
ized standardized uptake values
for the same slice and along two
specific projections highlighted in
red
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spinal districts and the SC was segmented by adjusting the
numerical parameters.
As shown in Fig. 2, the disease did not affect the anatom-
ical features of the spinal canal or the SC. The spinal cord
volume was similar in ALS patients and in control subjects,
both in the cervical district (32.08 ± 7.12 mL vs. 31.36 ±
5.99 mL, respectively, p = 0.79) and in the dorsal district
(65.60 ± 10.09 mL vs. 68.84 ± 12.61 mL, respectively, p =
0.10,; Fig. 2a–e).The extracted SC volume was also similar
in patients and control subjects both in the cervical segment
(13.99 ± 1.42 mL vs. 13.53 ± 1.60 mL, respectively, p = 0.47,
ns) and in the dorsal segment (32.60 ± 3.22 mL vs. 32.81 ±
4.25 mL, respectively, p = 0.56; Fig. 2b). As for the spinal
canal, ideal body weight was directly correlated with overall
SC volume in control subjects, but the significance of this
relationship was lower in ALS patients (Fig. 2f).
Spinal canal and spinal cord metabolic activity
On visual inspection, the radioactivity distribution within the
SC was relatively homogeneous without any focal areas of
enhanced uptake in both control subjects and ALS patients
(Fig. 3a, b). As shown in Fig. 3c–e, the average NSUV was
not significantly different between the two groups in the
whole spinal canal or in the cervical and dorsal districts. As
expected, the average NSUV was significantly lower than the
corresponding SC_NSUV in the same districts in both groups
(Fig. 3c). By contrast, the radioactivity distribution in the SC
showed a different pattern. FDG uptake in the SC was higher
in ALS patients than in controls. This difference in FDG up-
take between the groups was statistically significant for the
whole SC (NSUV 0.82 ± 0.28 in ALS patients vs. 0.70 ±
0.14 in controls, p < 0.05) and for the cervical segment
(NSUV 0.99 ± 0.37 vs. 0.85 ± 0.20, respectively; p < 0.05,
Fig. 3c, d), but not for the dorsal segment (NSUV 0.72 ±
0 . 2 4 v s . 0 . 6 2 ± 0 . 1 8 , r e s p e c t i v e l y ; p = 0 . 0 8 ;
Fig. 3e).Interestingly, the effect of ALS on FDG accumulation
in the SC was independent of demographic and clinical vari-
ables. In fact, SC_NSUV did not correlate with age, sex,
ALSFRS-R score, time elapsed from diagnosis to PET/CT
or riluzole treatment (Fig. 4).
Spinal cord metabolic pattern and patient outcomes
The potential prognostic value of metabolic information was
suggested by the observation that the 13 patients who died
showed a higher SC_NSUV than the 17 patients who were
still alive at 36 months (0.71 ± 0.26 vs. 0.55 ± 0.16, respec-
tively, p < 0.05; Fig. 4f). This result was confirmed byKaplan-
Meier analysis showing that the 16 patients with NSUVabove
the fifth decile had a significantly higher mortality rate than
those with NSUV below the fifth decile at 36 months after
PET/CT imaging (log-rank test, p < 0.01; Fig. 5).
In the univariate analysis, the only predictive variable for
overall survival was SC_NSUV (Table 2). The multivariate
analysis confirmed the independent prognostic value of the
SC metabolic pattern (hazard ratio, HR, 24.3, 95 % confi-
dence interval, CI, 2.2 – 262.8) although the strength of the
association needs to be confirmed in a large sample. Prognosis
was not associated with age, ALSFRS-R score, time from
diagnosis to PET scanning or the presence/absence of riluzole
treatment. A significantly increased risk of death was found
for male gender (HR 4.43, 95 % CI 0.87 – 22.5), and with
borderline significance with age (p = 0.055) and ALSFRS-R
score (p = 0.082), but there was no trend in risk with increas-
ing or decreasing age or ALSFRS-R score. On the other hand,
there was no significant difference in ALSFRS-R score at the
time of PET scanning between those who had died and those
who were still alive at 36 months (39.61 ± 3.5 vs. 38.76 ±
6.66, p = 0.7).
Discussion
The present study is the first attempt to estimate the metabolic
pattern of the spinal canal and SC from whole-body PET/CT
images. The results obtained indicate that this computational
approach might be a new method for exploring the status of
Table 1 Demographic characteristics of patient populations
Characteristic Control subjects ALS patients
Age (years)
Mean ± SD 60 ± 13 66 ± 11




Ideal body weight (kg), mean ± SD 66 ± 9 66 ± 9
Time from ALS diagnosis to PET/CT (months)
Mean ± SD – 18 ± 15
Median (range) – 17 (2 – 69)
ALS functional rating scale score
Mean ± SD – 39 ± 5
Median (range) – 39 (20 – 46)
Riluzole therapy, n – 21
Serum glucose (mg/dL)
Mean ± SD 98 ± 13 102 ± 12
Median (range) 100 (73 – 130) 98 (69 – 129)
Follow-up after PET/CT (months)
Mean ± SD 24 14 ± 7
Median (range) – 16 (1 – 36)
Number of deaths during follow-up 0 13
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the SC in different conditions, besides its potential to comple-
ment the routine analysis of ALS patients.
Recognition and measurement of spinal canal and spinal
cord by CTanalysis
Estimation of the canal space throughout the whole spine was
based on the assumption that compact bone is the human
tissue with the highest X-ray attenuation coefficient and can
thus be easily identified and extracted in each CT slice. This
computational approach is commonly used in commercially
available software for 3D representation of the skeleton, and
its potential has been previously validated in our laboratory
for the characterization of intraosseous volume and bone mar-
rowmetabolic activity [15, 25, 26]. However, thresholding the
Hounsfield values on the CT images is not effective in this
application since the spinal canal is not directly surrounded by
osseous tissue in all slices. To overcome this problem, we
developed a pattern recognition method based on the Hough
transform that permitted determination of canal shape also in
segments between the different vertebral bodies. This
approach permitted extraction of PET data and analysis of
FDG uptake throughout the whole SC in a systematic fashion.
The most relevant feature of our algorithm is its fully deter-
ministic nature with the user being asked to identify only the
occipital skull border and the caudal face of D12. This plane
was arbitrarily set as the caudal edge of the SC because of the
limited resolution of CT images that prevented accurate evalu-
ation of more distal segments. On the other hand, the operator-
independent nature of this method virtually abolished the need
for statistical analysis of its reproducibility measured in terms of
either interobserver or intraobserver variability.
FDG and spinal cord involvement in ALS
As a first validation step, we applied this method to a cohort of
ALS patients. This model fitted our purpose due to the path-
ological evidence of significant damage to the SC neurons [1,
2]. By contrast, spinal onset ALS was associated with a slight
yet significant increase in SC uptake of FDG. Several consid-
erations support the concept that this finding reflects an in-
creased metabolism of SC structures. First, the increase in
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Fig. 2 a Sagittal whole-body CTscan (left) and the corresponding image
showing extraction of the cervical (red) and dorsal (green) spinal canal.
b–d Volumes of the spinal canal (solid bars) and spinal cord (hatched
bars) in the control subjects (CTR) and in the 30 ALS patients (ALS): b
total volumes, c cervical region, d dorsal region. There are no differences
between the control subjects and ALS patients. e, f Linear regression
analysis of the relationship between spinal canal volume (e) and spinal
cord volume (f) and ideal body weight
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Secondly, it was not related to abnormal regulation of serum
glucose levels [27]. Finally, the difference between controls
and ALS patients virtually disappeared when the whole spinal
canal was considered, most likely because of both the smooth-
ing effect of the large volume and the spillover of radioactivity
uptake into surrounding outside tissues.
The increased FDG uptake in ALS SC at least partially
conflicts with the expected reduction in tissue metabolic rate
caused by the neuronal loss that has been described not only in
the motor cortex but also in the anterior horns of the SC in
ALS patients. Similarly, it partially disagrees with the emerg-
ing prognostic value of frontal hypometabolism in subgroups
of ALS patients [4, 5, 28]. Nevertheless, it has been extensive-
ly documented in the literature that neuroinflammation is a
key-signalling event in ALS [10]. This concept originated
from pathology studies showing activation of microglia and
astrocytes, as well as the presence of lymphocytes and mac-
rophages in post-mortem tissue from the motor cortex and SC
of both patients and experimental models of ALS [29, 30]. As
a common interpretation, these studies suggested that activat-
ed microglia might accumulate within the degenerating areas
and might contribute to propagating and sustaining the tissue
damage through the release of free radicals and other neuro-
toxic substances such as glutamate [30–32]. More recently,
this mechanism has been shown to also occur in the early
disease phases. In fact, different studies have shown inflam-
matory microglial activation in various cortical areas of ALS
patients using PET imaging and different tracers targeting the
translocator protein TSPO [6–8]. In this line, our observation
of a relative increase in SC FDG uptake might extend the
previously documented pattern of motor cortex damage in
ALS to lower motor neurons and might reflect inflammatory
mechanisms rather than the expected consequences of motor
neuron loss and subsequent SC atrophy.
FDG uptake cannot be considered per se a specific marker
of microglia activation. Nevertheless, the relevance of inflam-
matory mechanisms on ALS progression is supported by the
follow-up evaluation. Indeed, the Kaplan-Meier analysis in-
dicated that higher FDG uptake significantly predicted a
higher mortality rate. The multivariate analysis confirmed this
finding and showed the independent prognostic value of SC
metabolism. The observed difference in prognosis between
patients with high and low FDG uptake was striking (HR
24). Nevertheless, the effective clinical potential of SC FDG











































Fig. 3 a, b Whole-body maximum intensity projection CT images
coregistered with the extracted PET data for the spinal cord in a control
subject (a CTR) and an ALS patient (b ALS). The PET data alone are also
shown for the corresponding SCs as the average SUV normalized to the
corresponding liver values (average NSUV) together with images of the
cervical and dorsal segments. c–e Average NSUV for the spinal canal
(solid bars) and spinal cord (hatched bars) in control subjects (CTR) and
30 ALS patients (ALS): c whole spinal cord/spinal canal, d cervical seg-
ment, e dorsal segment. FDG uptake in the spinal cord was significantly
lower in control subjects for the whole spinal cord (c) and for the cervical
segment (d), but not for the dorsal segment (e). *p < 0.05
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Fig. 4 a, c, e Linear regression
analysis of the relationship
between spinal cord (SC) NSUV
and patient age (a), time between
diagnosis and imaging (c) and
revised ALS functional rating
scale (ALSFR-S) score (e). b, d, f
The spinal cord metabolic pattern
(in terms of NSUV) was not
significantly different between
male (M) and female (F) patients
(b), or between those treated and
those not treated with riluzole (d),
but SC NSUV was significantly
higher in patients who had died
(Nonsurvivors) than in those who
were still alive (Survivors) at the
end of the 36-month follow-up





















Time from PET/CT scan (months)
SC average SUV < 5th decile SC average SUV > 5th decile
Log Rank p = 0.01 
Fig. 5 Kaplan-Meier curves
showing overall survival in
patients with SC_NSUVabove
and below the fifth decile. High
FDG uptake in the whole spinal
cord was associated with a higher
mortality rate
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uptake in outcome prediction could not be assessed in the
present study because of the limited number of patients, the
retrospective nature of the evaluation and particularly the fact
that this hypothesis was generated by our study and needs to
be validated on independent datasets.
The fact that there were 17 patients censored before death
does not imply any risk of bias because these were not patients
lost to follow-up, but patients with recent enrolment.
Furthermore, they were similarly distributed in the two groups
of patients with SUV below and above the median. A similar
consideration also applies to the exclusion of patients with
bulbar onset disease: this decision – justified by the focus of
our computational algorithm on SCmetabolism – prevents the
ability to define the clinical value of this information. Finally,
the relatively small number of patients studied together with
the exclusion of subjects with bulbar onset ALS prevented
verification of the potential added value of SC metabolism
with respect to brain FDG uptake. Nevertheless, if confirmed
in larger prospective studies, the prognostic significance of SC
metabolic pattern would indicate a relevant role for SC inflam-
matory response in ALS progression.
In conclusion, the present study showed the potential of
Hough transform in delineating the spinal canal and SC in
clinical PET/CT scanning. As a first validation step, this meth-
od was applied to a cohort of ALS patients as a model of
pathologically confirmed damage to the SC neurons.
However, its use can obviously be extended to different condi-
tions in which the possibility of extracting the spinal canal and
its contents might be a useful tool to precisely evaluate the site
of SC injury from whatever cause and particularly to improve
the accuracy in monitoring its evolution. In this setting, the
proposed computational approach to PET/CT images would
permit the limitations of visual inspection to be overcome, lim-
itations that have so far hampered the evaluation of SC damage
in patients with inflammatory diseases [33], posttraumatic con-
ditions [34], cancer infiltration [35] or autoimmune/
autotoxicity disorders [36]. Similarly, its use in combination
with tracers selectively targeting specific neuronal functions
might contribute to the understanding of SC involvement in
different diseases.
As far as ALS is concerned, the availability of this bio-
marker and its operator-independent nature could be invalu-
able for the development of new therapeutic approaches, es-
pecially in early phase clinical trials in which current entry
criteria that consider only phenotype, disability severity and
disease duration markedly hamper the correct identification of
target patients.
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